N/A N=74 We-PAP: A Couples-based Intervention for Sleep Apnea
Obstructive Sleep Apnea
Primary: Recruitment Feasibility — 42; 42 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Phase 4 N=105 Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration (nAMD)
Primary: Incidence and Characteristics of Treatment-emergent Adverse Events During the 56 Weeks of Treatment With Brolucizumab. — 67; 50; 45; 9 Participants
N/A N=93 A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion · Infantile Fibrosarcoma
Primary: Time to Medical Treatment Failure — NA; NA; NA; 24.0 months — p=0.0058
Phase 3 N=520 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Phase 1 N=27 Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Solid Tumors · Lymphoma
Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) of LMP744 (NSC 706744) — 190 mg/m^2
N/A N=30 Improving Pain Management and Opioid Safety for Patients With Cirrhosis
Cirrhosis, Liver
Primary: Number of Participants Attending ≥80% of Intervention Sessions — 16; 5 Participants
N/A N=12 Post-stroke Fatigue, Inflammation, tDCS
Stroke · Fatigue · Chronic Stroke
Primary: Change in Fatigue Severity Scale (FSS) Score — -0.4; 0.2 units on a scale
Phase 3 N=125 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52 — 2.57; 1.92 scores on a scale — p=0.2441
N/A N=198 The Comparison of Energy in Take and Body Weight EXERCISE
Exercise · Energy · Body Weight
Primary: A Comparison of the Effects of Energy Balance With Three Groups. [Energy Intake, Adjusted DLW] — 123.6; 90.7; -2.3 kcal/day
Phase 2 N=81 Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival (rPFS) — 6.4; 14.8 months
Phase 4 N=100 Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
Asthma
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) — 3; 9 Participants
N/A N=30 Dietary Assessment Study Via Digital Images
Diet Habit
Primary: Weighed Food Intake — 354.4; 354.4 grams
N/A N=379 Comparative Effectiveness Study Telerehab Versus Conventional
Multiple Sclerosis
Primary: Timed 25 Foot Walk Test (T25FWT) — 2.88; 2.62; 3.41; 3.26 feet per second — p=<0.01